jetcityimage/iStock Editorial via Getty Images
- Eli Lilly (NYSE:LLY) has received traditional approval for its drug Retevmo for the treatment of a type of thyroid cancer.
- The FDA approved the product for the treatment of advanced or metastatic medullary thyroid cancer with a RET mutation, as detected
